{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-018223","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.167055+00:00","generated_at":"2026-05-26T01:52:30.417586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Natera Q4 revenue $476M (+53% YoY); guides 2025 revenue $1.87-1.95B","bullets":["Q4 total revenue $476.1M (+53% YoY); product revenue $472.9M (+53.9%).","Q4 gross margin 62.9% vs 51.4% a year ago; FY2024 GM 60.3%.","Q4 net loss $53.8M ($0.41/share) vs $78.0M ($0.65) in Q4 2023; op loss $64.7M.","Oncology tests in Q4 150,800 (+54.7% YoY); total tests 792,800 (+26.5%).","FY2025 guidance: rev $1.87-1.95B; GM ~60-64%; positive net cash inflow."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-018223","json":"https://secwatch.observer/filing/0001104659-25-018223.json","markdown":"https://secwatch.observer/filing/0001104659-25-018223.md","text":"https://secwatch.observer/filing/0001104659-25-018223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925018223/0001104659-25-018223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925018223/tm257259d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:52:30.417586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}